Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464020 | 0.80 | MAPK14 (0.51) | MAPK14GRM5PTGS2P2RX7PTGER1 | |
| SCHEMBL5460475 | 0.80 | MAPK14 (0.53) | MAPK14PTGS2P2RX7PTGER1RARG | |
| SCHEMBL5458504 | 0.77 | MAPK14 (0.48) | MAPK14KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL5458513 | 0.77 | MAPK14 (0.48) | MAPK14KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL5458481 | 0.76 | MAPK14 (0.52) | MAPK14PTGS2KMT2A | |
| SCHEMBL14592091 | 0.76 | CSF1R (0.47) | MAPK14RARGRORCMEN1KMT2A | |
| SCHEMBL5458670 | 0.75 | MAPK14 (0.41) | MAPK14KDM4EALDH1A1RARGRORC | |
| SCHEMBL5466720 | 0.75 | MAPK14 (0.48) | MAPK14KDM4EALDH1A1PTGER1RARG | |
| SCHEMBL5212963 | 0.74 | MAPK14 (0.54) | MAPK14KDM4EALDH1A1HPGDFYN | |
| SCHEMBL6105823 | 0.73 | ALDH1A1 (0.43) | MAPK14KDM4EALDH1A1PTGER1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | MAPK14 2533/4885GRM5 2749/4885PTGS2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.